Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer

LESSONS LEARNED. Vandetanib at a dose of 300 mg orally every day plus bortezomib 1.3 mg/m(2) intravenously on days 1, 4, 8, and 11 could be administered safely. Assessing outcomes in 17 patients with medullary thyroid cancer, investigators considered the combination to be more difficult to administe...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncologist
Egile Nagusiak: Del Rivero, Jaydira, Edgerly, Maureen, Ward, Jean, Madan, Ravi A., Balasubramaniam, Sanjeeve, Fojo, Tito, Gramza, Ann W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Inc. 2018
Gaiak:
Clinical Trial Results
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324636/
https://ncbi.nlm.nih.gov/pubmed/30297385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0452
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak